Finally, given the presence of PSMA on the neovasculature of other tumour types, including salivary gland tumours, renal cancer, hepatocellular carcinoma, and gliomas, there are ongoing clinical trials investigating the role of PSMA-targeted RLT in non-prostate malignancies, which is summarised in Supplementary Table S2. The gene discussed is FOLH1; the disease is central nervous system cancer.